About Transforming growth factor beta-1 proprotein
Transforming growth factor beta-1 proprotein (TGFB1) is a protein
from Homo sapiens identified by UniProt accession
P01137, 390 residues long.
MolForge cross-references it against 0 known binders and
2,766 disease associations.
Target properties
| Protein name | Transforming growth factor beta-1 proprotein |
| UniProt accession | P01137 |
| Gene | TGFB1 |
| Organism | Homo sapiens |
| Length | 390 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (2766)
Diseases linked to this target (Open Targets).
- Camurati-Engelmann disease · score 0.80
- inflammatory bowel disease, immunodeficiency, and encephalopathy · score 0.69
- myelodysplastic syndrome · score 0.57
- cancer · score 0.53
- anemia (phenotype) · score 0.48
- Beta-thalassemia · score 0.47
- Encephalopathy · score 0.46
- immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections syndrome · score 0.45
- cystic fibrosis · score 0.44
- genetic disorder · score 0.40
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P01137-F1 | alphafold | PREDICTED | 79.59 | — |
Amino-acid sequence (390 residues)
MPPSGLRLLP LLLPLLWLLV LTPGRPAAGL STCKTIDMEL VKRKRIEAIR GQILSKLRLA SPPSQGEVPP GPLPEAVLAL YNSTRDRVAG ESAEPEPEPE ADYYAKEVTR VLMVETHNEI YDKFKQSTHS IYMFFNTSEL REAVPEPVLL SRAELRLLRL KLKVEQHVEL YQKYSNNSWR YLSNRLLAPS DSPEWLSFDV TGVVRQWLSR GGEIEGFRLS AHCSCDSRDN TLQVDINGFT TGRRGDLATI HGMNRPFLLL MATPLERAQH LQSSRHRRAL DTNYCFSSTE KNCCVRQLYI DFRKDLGWKW IHEPKGYHAN FCLGPCPYIW SLDTQYSKVL ALYNQHNPGA SAAPCCVPQA LEPLPIVYYV GRKPKVEQLS NMIVRSCKCS
Explore Transforming growth factor beta-1 proprotein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets